# OmniAb

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/omniab
Canonical HTML page: https://getfinancebrief.com/entity/omniab

## Recent coverage (1 stories)

### OmniAb and PepGen Q4 Results Highlight Divergent Biotech Growth Strategies
2026-03-05 05:51:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors. While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.
Full story: https://getfinancebrief.com/story/omniab-pepgen-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.